Starting a GLP-1 medication is not a single decision made on day one. The first prescription is the opening move in a process that unfolds over months, and much of what shapes your experience happens after it: how the dose is stepped up, when it is held steady, and when it is lowered. That process is called GLP-1 dose adjustment (clinicians also call it titration), and it is one of the clearest examples of what individualized care looks like in real life rather than in a marketing slogan.
Two people can begin the same medication in the same week and end up on different schedules six months later. That is not a sign that one of them is doing something wrong. It is what happens when a licensed provider makes dose decisions based on how you feel, how you are responding, your health history, and how treatment fits into daily life. This guide explains how those decisions are made, what a provider considers before changing a dose, and how you can be an active partner in the process. It is general education, not a dosing chart, and your own schedule is always set by your prescriber.
What GLP-1 Dose Adjustment Actually Means
Dose adjustment is the gradual changing of a medication’s dose to find the level that works best for a specific person. With semaglutide and tirzepatide, treatment typically begins at a low dose, moves up in steps, and eventually settles at a steady long-term dose, often called the maintenance dose. Each step is meant to give the body time to adapt before the next one.
Dose adjustment serves two goals at once. The first is comfort: giving your digestive system and appetite signals time to adjust so that treatment stays manageable enough to continue. The second is effect: finding a dose that meaningfully supports appetite regulation and weight management for you. A good schedule balances the two, and the balance point differs from person to person.
It also helps to be clear about what dose adjustment is not. It is not a countdown to the highest available strength, and it is not a race. The FDA-posted prescribing information for both brand-name semaglutide and brand-name tirzepatide directs clinicians to consider how a patient is responding and how well they are tolerating treatment when choosing a maintenance dose, which is a built-in acknowledgment that the right dose is a clinical judgment rather than a fixed destination. You can read that language yourself in the FDA-posted prescribing information for brand-name semaglutide and the FDA-posted prescribing information for brand-name tirzepatide.
Why Treatment Starts Low
GLP-1 medications work in part by acting on appetite signaling and slowing how quickly the stomach empties. Those same actions explain why the most common side effects are digestive: nausea, constipation, diarrhea, reflux, and a feeling of fullness that arrives sooner than expected. In the STEP 1 trial of semaglutide, which followed adults with obesity for 68 weeks, digestive side effects were the most commonly reported. The published schedules for both medications state that stepping up gradually is intended to reduce the risk of those reactions.
That is the reason for the slow start. A low initial dose lets your body get used to the medication before the amount increases. Labeling for brand-name tirzepatide describes its starting dose as being for treatment initiation and not approved as a maintenance dose, and the lower semaglutide steps are described the same way. In plain terms, the early doses are built to help you adjust to treatment, not to be the dose that delivers the full effect.
This matters for expectations. If you judge a medication by how it feels or performs in the first few weeks, you may be judging the on-ramp rather than the road. Our guides to the first month on semaglutide and the first 90 days on tirzepatide cover what people commonly notice early on, and the week-by-week GLP-1 timeline shows how those changes tend to unfold. Gradual dose adjustment is the reason the timeline looks the way it does.
What Published Dosing Schedules Look Like
Looking at the schedules published for the brand-name products helps illustrate the general approach. For brand-name semaglutide injection, the labeled adult schedule starts at 0.25 mg once weekly for four weeks, then steps up at four-week intervals, with a maintenance dose of either 1.7 mg or 2.4 mg. For brand-name tirzepatide, the labeled schedule starts at 2.5 mg once weekly for four weeks, increases to 5 mg, and may then rise in 2.5 mg increments after at least four weeks on the current dose. Its recommended maintenance doses for weight reduction are 5 mg, 10 mg, or 15 mg. Both schedules appear in the dosage and administration sections of the FDA-posted labels linked above.
Two features of those schedules deserve attention. The first is the phrase “at least four weeks.” That is a minimum interval, not a deadline, and nothing in the labeling requires a patient to move up the moment four weeks have passed. The second is that the long-term dose is expressed as a range. Brand-name tirzepatide lists three acceptable maintenance doses, and brand-name semaglutide lists two. A range exists precisely because response and comfort vary between people.
One important clarification: Medica Weight Loss dispenses compounded semaglutide and tirzepatide, which are not the brand-name products described in those labels. The schedules above are a reference for how dose escalation is generally structured, not a dosing chart for any compounded prescription. Your prescriber determines your schedule based on your own evaluation, and you should follow their instructions rather than any published table.
The Factors a Provider Weighs Before Changing a Dose
A dose change is a decision made with information. Here is what a provider typically considers when deciding whether to increase, hold, or reduce a dose.
- How you are tolerating the current dose. Nausea, constipation, reflux, fatigue, or appetite that has become so suppressed that eating enough is difficult all bear on the decision. A dose that is working but barely manageable is often a reason to wait rather than climb.
- How you are responding. Providers look at trends over several weeks rather than single-day changes on the scale. Shifts in appetite, cravings, portion sizes, energy, and other health markers all count as response.
- Time on the current dose. Each dose needs time to show its effect. Increasing too quickly can make it hard to tell whether a new dose is helping or simply adding side effects.
- Your health history and other medications. Both medications carry a boxed warning, the label’s most prominent safety warning, about thyroid C-cell tumors seen in rodents, and they should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other medications matter too. The tirzepatide labeling notes possible interactions with insulin and insulin secretagogues, and it advises people using oral contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase.
- Other conditions being managed. The tirzepatide label lists different recommended maintenance doses for weight reduction and for obstructive sleep apnea, where 10 mg or 15 mg is recommended. Conditions like sleep apnea and high blood pressure can shape treatment goals, as we explain in our article on medical weight loss for sleep apnea and high blood pressure.
- Real-life circumstances. Travel, illness, a stomach bug, a stressful stretch at work, or an upcoming procedure can all affect whether it is a good time to change a dose. If you travel often, our guide to traveling with weight loss medication covers the practical side.
- Your goals and preferences. Some patients want steady progress, others prioritize comfort, and others mainly want to improve specific health markers. A provider who knows your priorities can weigh them against the clinical picture.
This is why the same medication can look so different from one patient to the next. The schedule is the output of many inputs, and no two people share exactly the same set.
Staying at a Dose Longer Is Not Falling Behind
Many patients assume that moving up on schedule means treatment is going well and staying put means it is stalling. The research does not support that idea. Both large registration trials were designed to compare several doses, and their results reflect averages across groups of people, not a promise for any individual.
In the SURMOUNT-1 trial of tirzepatide, adults with obesity who received 5 mg, 10 mg, or 15 mg weekly lost an average of 15.0%, 19.5%, and 20.9% of body weight at 72 weeks, compared with 3.1% with placebo, alongside lifestyle intervention. In STEP 1, participants on semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks, compared with 2.4% with placebo. Those were trials of brand-name products, and results with compounded formulations have not been established in the same studies. Individual outcomes vary widely, and these figures should not be read as an expectation for any patient.
What the data do show is that meaningful average responses were seen across a range of doses, which is consistent with the labeling’s acknowledgment that more than one maintenance dose can be appropriate. It is also why a provider may decide that a lower maintenance dose is the right fit for a patient who is responding well and feeling comfortable on treatment. Reaching a strength that works for you is the goal, not reaching the top of the chart.
When a Provider May Hold, Slow, or Step Back
Sometimes the right move is to pause the climb. Prescribing information for brand-name semaglutide says that if a patient does not tolerate a dose during escalation, clinicians may consider delaying the next increase for four weeks. Brand-name tirzepatide labeling says that if a patient does not tolerate a maintenance dose, a lower maintenance dose can be considered. In other words, holding or stepping back is built into standard practice rather than treated as a failure.
Common reasons a provider may recommend holding steady or reducing include persistent nausea or vomiting, difficulty keeping up with fluids, constipation that is not responding to basic measures, or appetite so low that you cannot get enough protein and calories. That last point is worth taking seriously. Eating too little can work against your goals, and protein intake in particular matters for preserving muscle during weight loss, which we discuss in our article on muscle loss and protein on semaglutide. Staying hydrated also makes a real difference to how you feel, and our guide to hydration on GLP-1 medications covers the basics.
Please do not change your dose on your own, whether that means skipping ahead, doubling up, or cutting back without guidance. Contact your provider and describe what is happening. Severe or persistent abdominal pain, repeated vomiting, signs of dehydration, or any symptom that worries you should be reported promptly, and a medical emergency calls for 911. For everyday side effects and how they are usually managed, see our guides to tirzepatide side effects and semaglutide side effects.
What Good Follow-Up Looks Like
Follow-up is what makes dose adjustment individualized. A provider cannot make a good dose decision without information, and the information comes from you. Medically supervised care with regular follow-up creates the opportunity to review how treatment is going and adjust before small problems become big ones.
Between check-ins, it is useful to keep simple notes on the things your provider will likely ask about:
- How your appetite and cravings have changed since the last dose change
- Any side effects, including when they occur in the week and how long they last
- Your typical protein and fluid intake
- Energy, sleep, and mood
- Your weight trend across several weeks rather than individual days
- Any new medications, supplements, illnesses, or travel
Patterns often show up in notes that are easy to miss in memory. For example, nausea that appears the day after each injection and fades by midweek tells a provider something different than nausea that lingers all week. A brief log turns a vague impression into usable information.
If your progress slows, that alone is not automatically a reason to increase the dose. Plateaus have many causes, including sleep, stress, protein intake, and the natural way the body responds to weight loss. Our article on why weight loss plateaus happen and how to break through explains them, and a provider can help sort out whether a dose change is part of the answer.
Questions to Bring to Your Next Check-In
Being prepared makes appointments more productive. Consider bringing questions like these:
- Based on how I am doing, is it a good time to stay at my current dose or move up?
- What would tell you that a dose change is warranted, and what would tell you to wait?
- Which side effects are expected, and which should prompt me to contact you right away?
- How should I handle a missed dose, a trip, or a period of illness?
- What should I be doing with protein, hydration, and movement to support treatment at this dose?
- What does a long-term plan look like once I reach a dose that is working?
These questions shift the conversation from “when do I go up?” to “what is the best plan for me?” which is the more useful frame.
Dose Decisions Continue After You Reach Your Steady Dose
Reaching your long-term dose does not mean the decision-making is over. Weight changes, health markers shift, life circumstances evolve, and a dose that was right six months ago may deserve a fresh look. A provider may review your dose periodically to confirm it is still the right fit, and that conversation may also include what you want the longer-term plan to be.
The same applies if you ever consider stopping or pausing treatment. Discuss it with your provider first rather than stopping abruptly, since they can help you plan for what to expect. After a long gap, providers sometimes choose to reintroduce a medication more gradually instead of resuming at the previous dose. Our article on what happens if you stop taking semaglutide or tirzepatide goes into what the research shows about discontinuation.
Frequently Asked Questions About GLP-1 Dose Adjustment
How often is a GLP-1 dose increased?
Published schedules for the brand-name products step up no faster than about every four weeks. That is a minimum interval, and many people stay at a dose longer. Your provider decides the pace based on how you are feeling and responding.
Do I need to reach the highest dose to get results?
No. Brand-name labeling lists a range of acceptable long-term doses for both semaglutide and tirzepatide and directs clinicians to consider response and how well a patient tolerates treatment. The right dose is the one that works for you at side effects you can manage.
What if I feel worse after a dose increase?
Let your provider know. They may recommend holding at the current dose, waiting before the next step, or stepping back, depending on your symptoms. Avoid making changes on your own.
Can I increase my dose myself if I am not seeing results?
No. Dose changes should come from your prescriber. Slower progress can have many causes unrelated to dose, and increasing without guidance can raise the likelihood of side effects.
Is the starting dose supposed to cause weight loss?
Starting doses are designed mainly to help your body adjust. Brand-name labeling describes them as starting doses rather than long-term doses. Some people notice appetite changes early, but the schedule is built around comfort and tolerance first.
Will my dose ever go down?
It can. A provider may lower a dose if side effects are hard to manage, if your appetite is suppressed too much, or if your needs change. Adjusting downward is a normal part of individualized care.
Do published brand-name schedules apply to my compounded prescription?
They illustrate how dose increases are generally structured, but they are not a dosing chart for a compounded prescription. Your prescriber sets your schedule after evaluating you, and you should follow their instructions.
Talk With a Provider About Your Plan
Dose adjustment is where individualized care becomes tangible. It is the series of small, informed decisions that turn a first prescription into a plan that fits your body and your life. If you are considering treatment, the first step is a consultation to find out whether medical weight loss is appropriate for you. Our guide on how to know if you are a good candidate for medical weight loss explains what providers look for, and our step-by-step guide to getting started with Medica walks through what happens next. You can also learn more about our semaglutide and tirzepatide treatment options, or start your consultation to speak with a licensed provider.
Medica Weight Loss offers compounded semaglutide and tirzepatide, prepared by a state-licensed compounding pharmacy based on a valid individual prescription. These compounded medications are not FDA-approved — they have not been evaluated by the FDA for safety, effectiveness, or quality. Any reference to FDA-approved medications elsewhere refers solely to brand-name formulations such as Wegovy®, Ozempic®, Zepbound®, and Mounjaro®, which are not what Medica Weight Loss dispenses.
